BUZZ - Market Watch: AbbVie’s strengths in immunology inject confidence in its long-term growth prospects

November 2 - ** AbbVie ABBV.N raised its annual profit forecast (link) after strong demand for its newly launched immunology and neuroscience drugs helped the company’s third-quarter results beat Wall Street estimates.

** The median target price among 32 brokerages covering the stock is $301.50; the average rating is “Buy” — according to data compiled by LSEG

Pipeline developments boost outlook

** Morgan Stanley (“Overweight”, target price: $346) said Skyrizi’s growth in immunology, as well as successful combination therapy for inflammatory bowel disease, will be key drivers for AbbVie’s results in 2027

** JPMorgan (“Overweight”, target price: $350) stated that AbbVie is among the best-positioned companies with strong core growth drivers, and its product pipeline (especially in immunology) provides a clearer outlook for revenue growth into the 2030s

** Guggenheim (“Buy”, target price: $322) commented that robust quarterly results reflect strong market demand for ABBV products and expects this business momentum to continue into the fourth quarter and through 2027

** Bernstein (“Market Perform”, target price: $275) said “the product pipeline is becoming increasingly attractive,” mainly due to its efforts to expand its immunology portfolio and opportunities within its oncology product suite

(To assist non-English speakers, Reuters has automatically translated its report into several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters does not accept any liability for any damage or loss caused by the use of the automated translation function.)